Utility of ¹⁸fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma.
Identifieur interne : 002D82 ( PubMed/Curation ); précédent : 002D81; suivant : 002D83Utility of ¹⁸fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma.
Auteurs : S. Horwitz ; B. Coiffier [France] ; F. Foss [États-Unis] ; H M Prince [Australie] ; L. Sokol [États-Unis] ; M. Greenwood [Australie] ; D. Caballero [Espagne] ; F. Morschhauser [France] ; L. Pinter-Brown [États-Unis] ; S P Iyer [États-Unis] ; A. Shustov [États-Unis] ; J. Nichols ; J. Balser ; B. Balser ; B. Pro [États-Unis]Source :
- Annals of oncology : official journal of the European Society for Medical Oncology [ 1569-8041 ] ; 2015.
Descripteurs français
- KwdFr :
- Antibiotiques antinéoplasiques (usage thérapeutique), Depsipeptides (usage thérapeutique), Fluorodésoxyglucose F18 (pharmacocinétique), Humains, Induction de rémission, Lymphome T périphérique (anatomopathologie), Lymphome T périphérique (imagerie diagnostique), Lymphome T périphérique (mortalité), Lymphome T périphérique (traitement médicamenteux), Pronostic, Radiopharmaceutiques (pharmacocinétique), Répartition dans les tissus, Résistance aux médicaments antinéoplasiques (), Stade de la tumeur, Taux de survie, Tomographie par émission de positons (utilisation), Études de suivi, Études prospectives.
- MESH :
- anatomopathologie : Lymphome T périphérique.
- imagerie diagnostique : Lymphome T périphérique.
- mortalité : Lymphome T périphérique.
- pharmacocinétique : Fluorodésoxyglucose F18, Radiopharmaceutiques.
- traitement médicamenteux : Lymphome T périphérique.
- usage thérapeutique : Antibiotiques antinéoplasiques, Depsipeptides.
- utilisation : Tomographie par émission de positons.
- Humains, Induction de rémission, Pronostic, Répartition dans les tissus, Résistance aux médicaments antinéoplasiques, Stade de la tumeur, Taux de survie, Études de suivi, Études prospectives.
English descriptors
- KwdEn :
- Antibiotics, Antineoplastic (therapeutic use), Depsipeptides (therapeutic use), Drug Resistance, Neoplasm (drug effects), Fluorodeoxyglucose F18 (pharmacokinetics), Follow-Up Studies, Humans, Lymphoma, T-Cell, Peripheral (diagnostic imaging), Lymphoma, T-Cell, Peripheral (drug therapy), Lymphoma, T-Cell, Peripheral (mortality), Lymphoma, T-Cell, Peripheral (pathology), Neoplasm Staging, Positron-Emission Tomography (utilization), Prognosis, Prospective Studies, Radiopharmaceuticals (pharmacokinetics), Remission Induction, Survival Rate, Tissue Distribution.
- MESH :
- chemical , pharmacokinetics : Fluorodeoxyglucose F18, Radiopharmaceuticals.
- chemical , therapeutic use : Antibiotics, Antineoplastic, Depsipeptides.
- diagnostic imaging : Lymphoma, T-Cell, Peripheral.
- drug effects : Drug Resistance, Neoplasm.
- drug therapy : Lymphoma, T-Cell, Peripheral.
- mortality : Lymphoma, T-Cell, Peripheral.
- pathology : Lymphoma, T-Cell, Peripheral.
- utilization : Positron-Emission Tomography.
- Follow-Up Studies, Humans, Neoplasm Staging, Prognosis, Prospective Studies, Remission Induction, Survival Rate, Tissue Distribution.
Abstract
For patients with peripheral T-cell lymphoma (PTCL), the value of (18)fluoro-deoxyglucose positron emission tomography (FDG-PET) scans for assessing prognosis and response to treatment remains unclear. The utility of FDG-PET, in addition to conventional radiology, was examined as a planned exploratory end point in the pivotal phase 2 trial of romidepsin for the treatment of relapsed/refractory PTCL.
DOI: 10.1093/annonc/mdv010
PubMed: 25605745
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002E58
Links to Exploration step
pubmed:25605745Curation
No country items
S. Horwitz<affiliation><nlm:affiliation>Lymphoma Division, Memorial Sloan-Kettering Cancer Center, New York, USA horwitzs@mskcc.org.</nlm:affiliation><wicri:noCountry code="subField">USA horwitzs@mskcc.org.</wicri:noCountry></affiliation><affiliation><nlm:affiliation>JNichols LLC, Swampscott.</nlm:affiliation><wicri:noCountry code="subField">Swampscott</wicri:noCountry></affiliation><affiliation><nlm:affiliation>Veristat, LLC, Holliston.</nlm:affiliation><wicri:noCountry code="subField">Holliston</wicri:noCountry></affiliation><affiliation><nlm:affiliation>Veristat, LLC, Holliston.</nlm:affiliation><wicri:noCountry code="subField">Holliston</wicri:noCountry></affiliation>Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Utility of ¹⁸fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma.</title><author><name sortKey="Horwitz, S" sort="Horwitz, S" uniqKey="Horwitz S" first="S" last="Horwitz">S. Horwitz</name><affiliation><nlm:affiliation>Lymphoma Division, Memorial Sloan-Kettering Cancer Center, New York, USA horwitzs@mskcc.org.</nlm:affiliation><wicri:noCountry code="subField">USA horwitzs@mskcc.org.</wicri:noCountry></affiliation></author><author><name sortKey="Coiffier, B" sort="Coiffier, B" uniqKey="Coiffier B" first="B" last="Coiffier">B. Coiffier</name><affiliation wicri:level="1"><nlm:affiliation>Department of Hematology, Hospices Civils de Lyon, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Hematology, Hospices Civils de Lyon, Lyon</wicri:regionArea></affiliation></author><author><name sortKey="Foss, F" sort="Foss, F" uniqKey="Foss F" first="F" last="Foss">F. Foss</name><affiliation wicri:level="1"><nlm:affiliation>Hematology Department, Yale Cancer Center, New Haven, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Hematology Department, Yale Cancer Center, New Haven</wicri:regionArea></affiliation></author><author><name sortKey="Prince, H M" sort="Prince, H M" uniqKey="Prince H" first="H M" last="Prince">H M Prince</name><affiliation wicri:level="1"><nlm:affiliation>Division of Cancer Medicine, Department of Haematology, Peter MacCallum Cancer Centre and University of Melbourne, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Division of Cancer Medicine, Department of Haematology, Peter MacCallum Cancer Centre and University of Melbourne</wicri:regionArea></affiliation></author><author><name sortKey="Sokol, L" sort="Sokol, L" uniqKey="Sokol L" first="L" last="Sokol">L. Sokol</name><affiliation wicri:level="1"><nlm:affiliation>Department of Malignant Hematology, Moffitt Cancer Center, Tampa, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Malignant Hematology, Moffitt Cancer Center, Tampa</wicri:regionArea></affiliation></author><author><name sortKey="Greenwood, M" sort="Greenwood, M" uniqKey="Greenwood M" first="M" last="Greenwood">M. Greenwood</name><affiliation wicri:level="1"><nlm:affiliation>Department of Haematology, Royal North Shore Hospital, Sydney, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Haematology, Royal North Shore Hospital, Sydney</wicri:regionArea></affiliation></author><author><name sortKey="Caballero, D" sort="Caballero, D" uniqKey="Caballero D" first="D" last="Caballero">D. Caballero</name><affiliation wicri:level="1"><nlm:affiliation>Hematology Department, Hospital Universitario de Salamanca, Salamanca, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Hematology Department, Hospital Universitario de Salamanca, Salamanca</wicri:regionArea></affiliation></author><author><name sortKey="Morschhauser, F" sort="Morschhauser, F" uniqKey="Morschhauser F" first="F" last="Morschhauser">F. Morschhauser</name><affiliation wicri:level="1"><nlm:affiliation>Department of Hematology, Hôpital Claude Huriez, CHU de Lille, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Hematology, Hôpital Claude Huriez, CHU de Lille</wicri:regionArea></affiliation></author><author><name sortKey="Pinter Brown, L" sort="Pinter Brown, L" uniqKey="Pinter Brown L" first="L" last="Pinter-Brown">L. Pinter-Brown</name><affiliation wicri:level="3"><nlm:affiliation>Division of Hematology-Oncology, UCLA Medical Center, Los Angeles.</nlm:affiliation><country>États-Unis</country><placeName><settlement type="city">Los Angeles</settlement><region type="state">Californie</region></placeName><wicri:orgArea>Division of Hematology-Oncology, UCLA Medical Center</wicri:orgArea></affiliation></author><author><name sortKey="Iyer, S P" sort="Iyer, S P" uniqKey="Iyer S" first="S P" last="Iyer">S P Iyer</name><affiliation wicri:level="3"><nlm:affiliation>Malignant Hematology, Houston Methodist Cancer Center, Houston.</nlm:affiliation><country>États-Unis</country><placeName><settlement type="city">Houston</settlement><region type="state">Texas</region></placeName><wicri:orgArea>Malignant Hematology, Houston Methodist Cancer Center</wicri:orgArea></affiliation></author><author><name sortKey="Shustov, A" sort="Shustov, A" uniqKey="Shustov A" first="A" last="Shustov">A. Shustov</name><affiliation wicri:level="4"><nlm:affiliation>Division of Hematology, University of Washington, Seattle.</nlm:affiliation><orgName type="university">Université de Washington</orgName><country>États-Unis</country><placeName><settlement type="city">Seattle</settlement><region type="state">Washington (État)</region></placeName></affiliation></author><author><name sortKey="Nichols, J" sort="Nichols, J" uniqKey="Nichols J" first="J" last="Nichols">J. Nichols</name><affiliation><nlm:affiliation>JNichols LLC, Swampscott.</nlm:affiliation><wicri:noCountry code="subField">Swampscott</wicri:noCountry></affiliation></author><author><name sortKey="Balser, J" sort="Balser, J" uniqKey="Balser J" first="J" last="Balser">J. Balser</name><affiliation><nlm:affiliation>Veristat, LLC, Holliston.</nlm:affiliation><wicri:noCountry code="subField">Holliston</wicri:noCountry></affiliation></author><author><name sortKey="Balser, B" sort="Balser, B" uniqKey="Balser B" first="B" last="Balser">B. Balser</name><affiliation><nlm:affiliation>Veristat, LLC, Holliston.</nlm:affiliation><wicri:noCountry code="subField">Holliston</wicri:noCountry></affiliation></author><author><name sortKey="Pro, B" sort="Pro, B" uniqKey="Pro B" first="B" last="Pro">B. Pro</name><affiliation wicri:level="1"><nlm:affiliation>Division of Hematology, Thomas Jefferson University, Philadelphia, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Hematology, Thomas Jefferson University, Philadelphia</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:25605745</idno><idno type="pmid">25605745</idno><idno type="doi">10.1093/annonc/mdv010</idno><idno type="wicri:Area/PubMed/Corpus">002E58</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002E58</idno><idno type="wicri:Area/PubMed/Curation">002D82</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002D82</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Utility of ¹⁸fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma.</title><author><name sortKey="Horwitz, S" sort="Horwitz, S" uniqKey="Horwitz S" first="S" last="Horwitz">S. Horwitz</name><affiliation><nlm:affiliation>Lymphoma Division, Memorial Sloan-Kettering Cancer Center, New York, USA horwitzs@mskcc.org.</nlm:affiliation><wicri:noCountry code="subField">USA horwitzs@mskcc.org.</wicri:noCountry></affiliation></author><author><name sortKey="Coiffier, B" sort="Coiffier, B" uniqKey="Coiffier B" first="B" last="Coiffier">B. Coiffier</name><affiliation wicri:level="1"><nlm:affiliation>Department of Hematology, Hospices Civils de Lyon, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Hematology, Hospices Civils de Lyon, Lyon</wicri:regionArea></affiliation></author><author><name sortKey="Foss, F" sort="Foss, F" uniqKey="Foss F" first="F" last="Foss">F. Foss</name><affiliation wicri:level="1"><nlm:affiliation>Hematology Department, Yale Cancer Center, New Haven, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Hematology Department, Yale Cancer Center, New Haven</wicri:regionArea></affiliation></author><author><name sortKey="Prince, H M" sort="Prince, H M" uniqKey="Prince H" first="H M" last="Prince">H M Prince</name><affiliation wicri:level="1"><nlm:affiliation>Division of Cancer Medicine, Department of Haematology, Peter MacCallum Cancer Centre and University of Melbourne, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Division of Cancer Medicine, Department of Haematology, Peter MacCallum Cancer Centre and University of Melbourne</wicri:regionArea></affiliation></author><author><name sortKey="Sokol, L" sort="Sokol, L" uniqKey="Sokol L" first="L" last="Sokol">L. Sokol</name><affiliation wicri:level="1"><nlm:affiliation>Department of Malignant Hematology, Moffitt Cancer Center, Tampa, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Malignant Hematology, Moffitt Cancer Center, Tampa</wicri:regionArea></affiliation></author><author><name sortKey="Greenwood, M" sort="Greenwood, M" uniqKey="Greenwood M" first="M" last="Greenwood">M. Greenwood</name><affiliation wicri:level="1"><nlm:affiliation>Department of Haematology, Royal North Shore Hospital, Sydney, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Haematology, Royal North Shore Hospital, Sydney</wicri:regionArea></affiliation></author><author><name sortKey="Caballero, D" sort="Caballero, D" uniqKey="Caballero D" first="D" last="Caballero">D. Caballero</name><affiliation wicri:level="1"><nlm:affiliation>Hematology Department, Hospital Universitario de Salamanca, Salamanca, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Hematology Department, Hospital Universitario de Salamanca, Salamanca</wicri:regionArea></affiliation></author><author><name sortKey="Morschhauser, F" sort="Morschhauser, F" uniqKey="Morschhauser F" first="F" last="Morschhauser">F. Morschhauser</name><affiliation wicri:level="1"><nlm:affiliation>Department of Hematology, Hôpital Claude Huriez, CHU de Lille, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Hematology, Hôpital Claude Huriez, CHU de Lille</wicri:regionArea></affiliation></author><author><name sortKey="Pinter Brown, L" sort="Pinter Brown, L" uniqKey="Pinter Brown L" first="L" last="Pinter-Brown">L. Pinter-Brown</name><affiliation wicri:level="3"><nlm:affiliation>Division of Hematology-Oncology, UCLA Medical Center, Los Angeles.</nlm:affiliation><country>États-Unis</country><placeName><settlement type="city">Los Angeles</settlement><region type="state">Californie</region></placeName><wicri:orgArea>Division of Hematology-Oncology, UCLA Medical Center</wicri:orgArea></affiliation></author><author><name sortKey="Iyer, S P" sort="Iyer, S P" uniqKey="Iyer S" first="S P" last="Iyer">S P Iyer</name><affiliation wicri:level="3"><nlm:affiliation>Malignant Hematology, Houston Methodist Cancer Center, Houston.</nlm:affiliation><country>États-Unis</country><placeName><settlement type="city">Houston</settlement><region type="state">Texas</region></placeName><wicri:orgArea>Malignant Hematology, Houston Methodist Cancer Center</wicri:orgArea></affiliation></author><author><name sortKey="Shustov, A" sort="Shustov, A" uniqKey="Shustov A" first="A" last="Shustov">A. Shustov</name><affiliation wicri:level="4"><nlm:affiliation>Division of Hematology, University of Washington, Seattle.</nlm:affiliation><orgName type="university">Université de Washington</orgName><country>États-Unis</country><placeName><settlement type="city">Seattle</settlement><region type="state">Washington (État)</region></placeName></affiliation></author><author><name sortKey="Nichols, J" sort="Nichols, J" uniqKey="Nichols J" first="J" last="Nichols">J. Nichols</name><affiliation><nlm:affiliation>JNichols LLC, Swampscott.</nlm:affiliation><wicri:noCountry code="subField">Swampscott</wicri:noCountry></affiliation></author><author><name sortKey="Balser, J" sort="Balser, J" uniqKey="Balser J" first="J" last="Balser">J. Balser</name><affiliation><nlm:affiliation>Veristat, LLC, Holliston.</nlm:affiliation><wicri:noCountry code="subField">Holliston</wicri:noCountry></affiliation></author><author><name sortKey="Balser, B" sort="Balser, B" uniqKey="Balser B" first="B" last="Balser">B. Balser</name><affiliation><nlm:affiliation>Veristat, LLC, Holliston.</nlm:affiliation><wicri:noCountry code="subField">Holliston</wicri:noCountry></affiliation></author><author><name sortKey="Pro, B" sort="Pro, B" uniqKey="Pro B" first="B" last="Pro">B. Pro</name><affiliation wicri:level="1"><nlm:affiliation>Division of Hematology, Thomas Jefferson University, Philadelphia, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Hematology, Thomas Jefferson University, Philadelphia</wicri:regionArea></affiliation></author></analytic><series><title level="j">Annals of oncology : official journal of the European Society for Medical Oncology</title><idno type="eISSN">1569-8041</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antibiotics, Antineoplastic (therapeutic use)</term><term>Depsipeptides (therapeutic use)</term><term>Drug Resistance, Neoplasm (drug effects)</term><term>Fluorodeoxyglucose F18 (pharmacokinetics)</term><term>Follow-Up Studies</term><term>Humans</term><term>Lymphoma, T-Cell, Peripheral (diagnostic imaging)</term><term>Lymphoma, T-Cell, Peripheral (drug therapy)</term><term>Lymphoma, T-Cell, Peripheral (mortality)</term><term>Lymphoma, T-Cell, Peripheral (pathology)</term><term>Neoplasm Staging</term><term>Positron-Emission Tomography (utilization)</term><term>Prognosis</term><term>Prospective Studies</term><term>Radiopharmaceuticals (pharmacokinetics)</term><term>Remission Induction</term><term>Survival Rate</term><term>Tissue Distribution</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Antibiotiques antinéoplasiques (usage thérapeutique)</term><term>Depsipeptides (usage thérapeutique)</term><term>Fluorodésoxyglucose F18 (pharmacocinétique)</term><term>Humains</term><term>Induction de rémission</term><term>Lymphome T périphérique (anatomopathologie)</term><term>Lymphome T périphérique (imagerie diagnostique)</term><term>Lymphome T périphérique (mortalité)</term><term>Lymphome T périphérique (traitement médicamenteux)</term><term>Pronostic</term><term>Radiopharmaceutiques (pharmacocinétique)</term><term>Répartition dans les tissus</term><term>Résistance aux médicaments antinéoplasiques ()</term><term>Stade de la tumeur</term><term>Taux de survie</term><term>Tomographie par émission de positons (utilisation)</term><term>Études de suivi</term><term>Études prospectives</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Fluorodeoxyglucose F18</term><term>Radiopharmaceuticals</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibiotics, Antineoplastic</term><term>Depsipeptides</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Lymphome T périphérique</term></keywords><keywords scheme="MESH" qualifier="diagnostic imaging" xml:lang="en"><term>Lymphoma, T-Cell, Peripheral</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Drug Resistance, Neoplasm</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Lymphoma, T-Cell, Peripheral</term></keywords><keywords scheme="MESH" qualifier="imagerie diagnostique" xml:lang="fr"><term>Lymphome T périphérique</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Lymphoma, T-Cell, Peripheral</term></keywords><keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Lymphome T périphérique</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Lymphoma, T-Cell, Peripheral</term></keywords><keywords scheme="MESH" qualifier="pharmacocinétique" xml:lang="fr"><term>Fluorodésoxyglucose F18</term><term>Radiopharmaceutiques</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Lymphome T périphérique</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antibiotiques antinéoplasiques</term><term>Depsipeptides</term></keywords><keywords scheme="MESH" qualifier="utilisation" xml:lang="fr"><term>Tomographie par émission de positons</term></keywords><keywords scheme="MESH" qualifier="utilization" xml:lang="en"><term>Positron-Emission Tomography</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Follow-Up Studies</term><term>Humans</term><term>Neoplasm Staging</term><term>Prognosis</term><term>Prospective Studies</term><term>Remission Induction</term><term>Survival Rate</term><term>Tissue Distribution</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Humains</term><term>Induction de rémission</term><term>Pronostic</term><term>Répartition dans les tissus</term><term>Résistance aux médicaments antinéoplasiques</term><term>Stade de la tumeur</term><term>Taux de survie</term><term>Études de suivi</term><term>Études prospectives</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">For patients with peripheral T-cell lymphoma (PTCL), the value of (18)fluoro-deoxyglucose positron emission tomography (FDG-PET) scans for assessing prognosis and response to treatment remains unclear. The utility of FDG-PET, in addition to conventional radiology, was examined as a planned exploratory end point in the pivotal phase 2 trial of romidepsin for the treatment of relapsed/refractory PTCL.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25605745</PMID><DateCreated><Year>2015</Year><Month>03</Month><Day>27</Day></DateCreated><DateCompleted><Year>2016</Year><Month>02</Month><Day>09</Day></DateCompleted><DateRevised><Year>2017</Year><Month>02</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1569-8041</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>4</Issue><PubDate><Year>2015</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Annals of oncology : official journal of the European Society for Medical Oncology</Title><ISOAbbreviation>Ann. Oncol.</ISOAbbreviation></Journal><ArticleTitle>Utility of ¹⁸fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma.</ArticleTitle><Pagination><MedlinePgn>774-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/annonc/mdv010</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">For patients with peripheral T-cell lymphoma (PTCL), the value of (18)fluoro-deoxyglucose positron emission tomography (FDG-PET) scans for assessing prognosis and response to treatment remains unclear. The utility of FDG-PET, in addition to conventional radiology, was examined as a planned exploratory end point in the pivotal phase 2 trial of romidepsin for the treatment of relapsed/refractory PTCL.</AbstractText><AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">Patients received romidepsin at a dose of 14 mg/m(2) on days 1, 8, and 15 of 28-day cycles. The primary end point was the rate of confirmed/unconfirmed complete response (CR/CRu) as assessed by International Workshop Criteria (IWC) using conventional radiology. For the exploratory PET end point, patients with at least baseline FDG-PET scans were assessed by IWC + PET criteria.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of 130 patients, 110 had baseline FDG-PET scans, and 105 were PET positive at baseline. The use of IWC + PET criteria increased the objective response rate to 30% compared with 26% by conventional radiology. Durations of response were well differentiated by both conventional radiology response criteria [CR/CRu versus partial response (PR), P = 0.0001] and PET status (negative versus positive, P < 0.0001). Patients who achieved CR/CRu had prolonged progression-free survival (PFS, median 25.9 months) compared with other response groups (P = 0.0007). Patients who achieved PR or stable disease (SD) had similar PFS (median 7.2 and 6.3 months, respectively, P = 0.6427). When grouping PR and SD patients by PET status, patients with PET-negative versus PET-positive disease had a median PFS of 18.2 versus 7.1 months (P = 0.0923).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Routine use of FDG-PET does not obviate conventional staging, but may aid in determining prognosis and refine response assessments for patients with PTCL, particularly for those who do not achieve CR/CRu by conventional staging. The optimal way to incorporate FDG-PET scans for patients with PTCL remains to be determined.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">NCT00426764.</AbstractText><CopyrightInformation>© The Author 2015. Published by Oxford University Press on behalf of the European Society for Medical Oncology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Horwitz</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Lymphoma Division, Memorial Sloan-Kettering Cancer Center, New York, USA horwitzs@mskcc.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coiffier</LastName><ForeName>B</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Hematology, Hospices Civils de Lyon, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Foss</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Hematology Department, Yale Cancer Center, New Haven, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prince</LastName><ForeName>H M</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>Division of Cancer Medicine, Department of Haematology, Peter MacCallum Cancer Centre and University of Melbourne, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sokol</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Malignant Hematology, Moffitt Cancer Center, Tampa, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greenwood</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Haematology, Royal North Shore Hospital, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caballero</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Hematology Department, Hospital Universitario de Salamanca, Salamanca, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morschhauser</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Hematology, Hôpital Claude Huriez, CHU de Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pinter-Brown</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of Hematology-Oncology, UCLA Medical Center, Los Angeles.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iyer</LastName><ForeName>S P</ForeName><Initials>SP</Initials><AffiliationInfo><Affiliation>Malignant Hematology, Houston Methodist Cancer Center, Houston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shustov</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Hematology, University of Washington, Seattle.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nichols</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>JNichols LLC, Swampscott.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Balser</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Veristat, LLC, Holliston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Balser</LastName><ForeName>B</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Veristat, LLC, Holliston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pro</LastName><ForeName>B</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Division of Hematology, Thomas Jefferson University, Philadelphia, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00426764</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>UL1 TR000371</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>01</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Ann Oncol</MedlineTA><NlmUniqueID>9007735</NlmUniqueID><ISSNLinking>0923-7534</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000903">Antibiotics, Antineoplastic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047630">Depsipeptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019275">Radiopharmaceuticals</NameOfSubstance></Chemical><Chemical><RegistryNumber>0Z5B2CJX4D</RegistryNumber><NameOfSubstance UI="D019788">Fluorodeoxyglucose F18</NameOfSubstance></Chemical><Chemical><RegistryNumber>CX3T89XQBK</RegistryNumber><NameOfSubstance UI="C087123">romidepsin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2005 Jul 20;23(21):4652-61</RefSource><PMID Version="1">15837965</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 1999 Apr;17(4):1244</RefSource><PMID Version="1">10561185</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>BMC Cancer. 2015;15:198</RefSource><PMID Version="1">25879747</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Nucl Med. 2008 May;33(5):365-6</RefSource><PMID Version="1">18431160</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mayo Clin Proc. 2012 Jun;87(6):571-80</RefSource><PMID Version="1">22677077</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Lymphoma Myeloma. 2008 Apr;8(2):94-9</RefSource><PMID Version="1">18501102</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Nucl Med. 2006 Oct;47(10):1622-7</RefSource><PMID Version="1">17015897</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2007 Feb 10;25(5):579-86</RefSource><PMID Version="1">17242396</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Hematol. 2008 Aug;87(8):613-21</RefSource><PMID Version="1">18509641</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2013 Jun 1;31(16):1970-6</RefSource><PMID Version="1">23610113</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2012 Feb 20;30(6):631-6</RefSource><PMID Version="1">22271479</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Leuk Lymphoma. 2007 Aug;48(8):1531-8</RefSource><PMID Version="1">17701584</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2011 Jun 23;117(25):6756-67</RefSource><PMID Version="1">21493798</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Oncol. 2007 Oct;18(10):1685-90</RefSource><PMID Version="1">17716987</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Oncol. 2011 Mar;22(3):705-11</RefSource><PMID Version="1">20739714</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2011 Mar 20;29(9):1182-9</RefSource><PMID Version="1">21245435</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Hematol Oncol. 2010;3:5</RefSource><PMID Version="1">20132536</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2008 Sep 1;26(25):4124-30</RefSource><PMID Version="1">18626005</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Leuk Lymphoma. 2012 Oct;53(10):1876-81</RefSource><PMID Version="1">22432519</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AJR Am J Roentgenol. 2010 Aug;195(2):333-40</RefSource><PMID Version="1">20651187</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Leuk Lymphoma. 2013 Oct;54(10):2163-7</RefSource><PMID Version="1">23369041</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Rev Drug Discov. 2006 Sep;5(9):769-84</RefSource><PMID Version="1">16955068</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Chem Biol. 2010 Mar;6(3):238-243</RefSource><PMID Version="1">20139990</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Curr Opin Oncol. 2007 Sep;19(5):438-43</RefSource><PMID Version="1">17762567</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2011 Jun 2;117(22):5827-34</RefSource><PMID Version="1">21355097</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Nucl Med. 2008 Nov;49(11):1783-9</RefSource><PMID Version="1">18927319</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Lymphoma Myeloma Leuk. 2013 Dec;13(6):664-70</RefSource><PMID Version="1">24035712</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nucl Med Commun. 2010 Mar;31(3):195-200</RefSource><PMID Version="1">20009963</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Hematol Oncol. 2014;7:11</RefSource><PMID Version="1">24456586</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000903" MajorTopicYN="N">Antibiotics, Antineoplastic</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D047630" MajorTopicYN="N">Depsipeptides</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019008" MajorTopicYN="N">Drug Resistance, Neoplasm</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019788" MajorTopicYN="N">Fluorodeoxyglucose F18</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016411" MajorTopicYN="N">Lymphoma, T-Cell, Peripheral</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName><QualifierName UI="Q000656" MajorTopicYN="Y">utilization</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019275" MajorTopicYN="N">Radiopharmaceuticals</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012074" MajorTopicYN="N">Remission Induction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014018" MajorTopicYN="N">Tissue Distribution</DescriptorName></MeshHeading></MeshHeadingList><OtherID Source="NLM">PMC4374388</OtherID><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">histone deacetylase inhibitor</Keyword><Keyword MajorTopicYN="N">peripheral T-cell lymphoma</Keyword><Keyword MajorTopicYN="N">positron emission tomography</Keyword><Keyword MajorTopicYN="N">radiology</Keyword><Keyword MajorTopicYN="N">romidepsin</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>1</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>1</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>2</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25605745</ArticleId><ArticleId IdType="pii">mdv010</ArticleId><ArticleId IdType="doi">10.1093/annonc/mdv010</ArticleId><ArticleId IdType="pmc">PMC4374388</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002D82 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 002D82 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:25605745
|texte= Utility of ¹⁸fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:25605745" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |